The new data indicate that leukotrienes, immune-system-signaling molecules previously thought to play a crucial role only in asthma, are also overabundant inside diseased arteries.
The public has mostly focused on Erbitux's ability to slow tumor growth by blocking epidermal growth factor receptor, a key growth-promoting protein that is overabundant in many cancer cells.